Join Growin Stock Community!

Sab biotherapeutics, inc.SABS.US Overview

US StockHealthcare
(No presentation for SABS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

SABS AI Insights

SABS Overall Performance

SABS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

SABS Recent Performance

-2.44%

Sab biotherapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

SABS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

SABS Key Information

SABS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

SABS Profile

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.

Price of SABS

SABS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

SABS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.96
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1701.76
PB Ratio
1.19
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
16338.32%
Revenue Growth (YoY)
-92.42%
Profit Growth (YoY)
-92.42%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.96
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1701.76
PB Ratio
1.19
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
16338.32%
Revenue Growth (YoY)
-92.42%
Profit Growth (YoY)
-92.42%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is SABS's latest earnings report released?

    The most recent financial report for Sab biotherapeutics, inc. (SABS) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating SABS's short-term business performance and financial health. For the latest updates on SABS's earnings releases, visit this page regularly.

  • Where does SABS fall in the P/E River chart?

    According to historical valuation range analysis, Sab biotherapeutics, inc. (SABS)'s current price-to-earnings (P/E) ratio is 8.23, placing it in the Overvalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • How much debt does SABS have?

    As of the end of the reporting period, Sab biotherapeutics, inc. (SABS) had total debt of 6.19M, with a debt ratio of 0.03. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does SABS have?

    At the end of the period, Sab biotherapeutics, inc. (SABS) held Total Cash and Cash Equivalents of 29.42M, accounting for 0.16 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is SABS's EPS continuing to grow?

    According to the past four quarterly reports, Sab biotherapeutics, inc. (SABS)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.5. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of SABS?

    Sab biotherapeutics, inc. (SABS)'s Free Cash Flow (FCF) for the period is -13.05M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 104.15% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of SABS?

    The latest valuation data shows Sab biotherapeutics, inc. (SABS) has a Price-To-Earnings (PE) ratio of 8.23 and a Price/Earnings-To-Growth (PEG) ratio of -0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.